Use an FDA-approved HRD* test that measures both BRCA mutations and genomic instability^1,2

Nearly half of the patients in the PAOLA-1 trial were HRD positive³

In a prespecified exploratory analysis of HRD-negative and HRD-unknown patients, there was insufficient evidence to suggest differential efficacy between the combination of LYNPARZA + bevacizumab and bevacizumab + placebo

*Select patients for this indication based on an FDA-approved companion diagnostic for LYNPARZA.¹

^†HRD positive was defined as either a tBRCA mutation and/or an HRD score ≥42 by Myriad MyChoice^® CDx; HRD negative was defined as non–tBRCA-mutated and an HRD score <42 by Myriad MyChoice^® CDx. 4.2% of the test results were missing, 2.1% failed, and 11.3% were inconclusive, yielding approximately 18% of the total PAOLA-1 population with an unknown HRD status.^6,7

^‡May include markers of genomic instability (eg, LOH, TAI, LST).²

Choose the only FDA-approved test for LYNPARZA + bevacizumab. Myriad MyChoice^® CDx identified up to 8% more HRD-positive tumors than an LOH-based assay.^1,8§

^§Does not distinguish between somatic and germline on reports.²

^||In a study of 148 tumor samples from patients with non-gBRCAm aOC following response to platinum-based chemotherapy, an LOH-based assay identified 40% as HRD positive compared with 48% using the Myriad MyChoice^® CDx.⁸

^¶If found to have a BRCA mutation, germline testing may inform genetic risk for patients and their families.⁹